EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Prevalence of Active HCV Infection in Spain in 2022 Using Multiparameter Evidence Synthesis

Christos Thomadakis iD, Ilias Gountas, Konstantinos Gountas, Nestor Nuño, Begoña Brime, Rosario Sendino, Agustín Albillos iD, María Buti, Javier Crespo, Juan Berenguer, Sonia Alonso, Alberto Díaz de Santiago und 16 weitere

Journal of Viral Hepatitis · 2026-04 · 33 (4)

DOI: 10.1111/jvh.70159 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Viral Hepatitis, online erschienen am 02.03.2026. Verfasst von Christos Thomadakis und 27 weiteren Autor:innen. Beteiligte Einrichtung: Medical School, University of Cyprus, Nicosia, Cyprus. Hauptthemen laut MEDLINE: Hepatitis C. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Ministry of Health, Spain.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hepatitis C virus (HCV) remains a major public health concern worldwide. Spain has implemented large‐scale direct‐acting antiviral (DAA) treatment programs, yet the prevalence of active HCV infection (aHCV) and its trends over time remain incompletely characterised. We applied Bayesian multiparameter evidence synthesis (MPES) to estimate the prevalence of aHCV in Spain in 2022 and its change from 2019 to 2022. The Spanish population aged 15–79 years was stratified into four non‐overlapping risk groups: current people who inject drugs (PWID), ex‐PWID, gay‐bisexual and other men who have sex with men (GBMSM) engaging in chemsex (GBMSMchem), and the general population. Data sources included, among others, national seroprevalence surveys, behavioural studies, national databases, and clinical records on DAA treatment outcomes. The estimated overall aHCV prevalence in Spain in 2022 was 0.14% (95% Credible Interval: 0.05%–0.27%), corresponding to approximately 54,500 individuals. Prevalence was highest among current PWID (12.5%) and GBMSMchem (8.4%). Compared to 2019, the total number of aHCV cases declined by ~20,000, largely attributable to DAA treatment. Among the general population, 29.4% of aHCV cases remained undiagnosed, with the highest prevalence in individuals aged 50–59 (0.25%) and 60–69 (0.16%) years. Spain has made substantial progress towards HCV elimination, but key populations such as PWID and GBMSMchem remain at high risk. Targeted interventions, including expanded harm reduction services and accessible HCV testing and treatment, are essential to achieving the World Health Organization (WHO) elimination targets by 2030.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hepatitis CSpainHumansPrevalenceMaleAdultMiddle AgedAdolescentAgedYoung AdultBayes TheoremHepacivirusSubstance Abuse, IntravenousAntiviral Agents

Stichwörter der Autor:innen

Bayesian evidence synthesisSpainactive HCV infectionkey populationspopulation prevalence

Substanzen

Antiviral Agents

Autor:innen und Institutionen

  • Medical School, University of Cyprus, Nicosia, Cyprus.
  • Department of Statistics, Athens University of Economics and Business, Athens, Greece.
  • TRAGSATEC, Madrid, Spain.
  • Spanish National Plan on Drugs, Ministry of Health, Madrid, Spain.
  • Ramón y Cajal University Hospital, Madrid, IRYCIS, Universidad de Alcalá, Madrid, Spain.
  • Center for Biomedical Research in Hepatology Diseases (CIBEREHD), Institute of Health Carlos III, Madrid, Spain.

ORCID-Profile: Christos Thomadakis, Agustín Albillos, Montserrat Laguno, Manuel Romero-Gómez

Förderung

  • Ministry of Health, Spain

Zitieren

APA

Thomadakis, C., Gountas, I., Gountas, K., Nuño, N., Brime, B., Sendino, R., Albillos, A., Buti, M., Crespo, J., Berenguer, J., Alonso, S., de Santiago, A. D., Hernando, V., Laguno, M., Lens, S., Diago, M., Montes, M. L., García-Samaniego, J., Morano, L., …, & Nikolopoulos, G. (2026). Prevalence of Active HCV Infection in Spain in 2022 Using Multiparameter Evidence Synthesis. Journal of Viral Hepatitis, 33(4). https://doi.org/10.1111/jvh.70159

Vancouver

Thomadakis C, Gountas I, Gountas K, Nuño N, Brime B, Sendino R, et al. Prevalence of Active HCV Infection in Spain in 2022 Using Multiparameter Evidence Synthesis. Journal of Viral Hepatitis. 2026;33(4). doi:10.1111/jvh.70159

BibTeX
@article{Thomadakis2026,
  author = {Thomadakis, Christos and Gountas, Ilias and Gountas, Konstantinos and Nuño, Nestor and Brime, Begoña and Sendino, Rosario and Albillos, Agustín and Buti, María and Crespo, Javier and Berenguer, Juan and Alonso, Sonia and de Santiago, Alberto Díaz and Hernando, Victoria and Laguno, Montserrat and Lens, Sabela and Diago, Moisés and Montes, Maria Luisa and García-Samaniego, Javier and Morano, Luis and Moreno, Juan Luis and Navarro, Jordi and Romero-Gómez, Manuel and Santos, Laura and Soriano, Raúl and Duffell, Erika and Diaz, Asuncion and Del Amo, Julia and Nikolopoulos, Georgios},
  title = {Prevalence of Active HCV Infection in Spain in 2022 Using Multiparameter Evidence Synthesis},
  journal = {Journal of Viral Hepatitis},
  year = {2026},
  volume = {33},
  number = {4},
  doi = {10.1111/jvh.70159}
}
Kostenlos starten →